Personalizing Care in MG


Expert neurologists discuss patient-focused care when it comes to treating MG, also highlighting clinical trials.

This is a video synopsis/summary of a panel discussion involving James Howard, MD; Nicholas Silvestri, MD, FAAN; Tuan Vu, MD; Ali Habib, MD; and Beth Stein, MD.

The conversation shifts to the effectiveness of targeted therapies in personalizing patient care for patients with myasthenia gravis (MG). Participants discuss the challenges of incorporating these therapies alongside existing treatments and effectively communicating options to patients. They emphasize the importance of breaking down complex information into manageable parts for both patients and providers.

Clinical trial participation is highlighted as crucial for advancing therapies, with recognition of patients' contributions and the benefits of improved access to care. However, there's concern about disparities in trial recruitment, particularly in North America, and the need for better outreach and adaptation of trial methodologies to ensure inclusivity.

The looming concern is whether current practices can sustain the demand for new therapies, given the growing pipeline and conceptualized treatments. This prompts a call for reflection on trial recruitment practices and potential regulatory hurdles to ensure continued progress in patient care.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.

Related Videos
A panel of 3 experts on Alzheimer's disease
A panel of 3 experts on Alzheimer's disease
Monica Verduzco-Gutierrez, MD
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
© 2024 MJH Life Sciences

All rights reserved.